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Abstract: 
Aim and background: Chronic inflammation associates with increased senescence, which is a 
strong predictor for cardiovascular disease. We hypothesised that inflammation accelerates 
senescence and thereby enhances the risk of cardiovascular disease in gout. 
Methods: We assessed replicative senescence by quantifying telomere length (TL) in a discovery 
cohort of 145 Dutch patients with gout and 273 healthy individuals and validated our results in 
474 patients with gout and 293 healthy participants from New-Zealand. Subsequently, we 
investigated the effect of cardiovascular disease on TL of all participants. Also, we measured TL 
of CD4+ and CD8+ T lymphocytes, B lymphocytes, monocytes, natural killer (NK) cells and 
plasmacytoid dendritic cells (pDCs). Additionally, we assessed the potential temporal difference 
in TL and telomerase activity. 
Results: TL in PBMCs of healthy donors decreased over time reflecting normal ageing. Patients 
with gout demonstrated shorter telomeres (P=0.001, R2=0.01873). In fact, the extent of telomere 
erosion in patients with gout was higher at any age as compared to healthy counterparts at any 
age (P<0.0001, R2=0.02847). Patients with gout with cardiovascular disease had the shortest 
telomeres and TL was an independent risk factor for cardiovascular disease in patients with gout 
(P=0.001). TL was inversely associated with the number of gouty flares (P=0.005). 
Conclusions: Patients with gout have shorter telomeres than healthy participants, reflecting 
increased cellular senescence. Telomere shortening was associated with the number of flares, and 
with cardiovascular disease in people with gout.  
  
Introduction 
Gout is a rheumatic disease characterized by deposition of monosodium urate (MSU) crystals in 
and around the joints, associated with elevated serum urate levels. Gout is the most common 
inflammatory arthritis in men older than 40 years and it affects 1-5% of adults in the Western 
populations [1–5]. Patients experience recurrent episodes of acute joint inflammation, and, in the 
presence of persistent hyperuricemia, may also develop chronic joint inflammation. We recently 
demonstrated that patients with gout display high levels of inflammatory mediators such as IL-8 
even though these patients did not have clinically apparent inflammatory disease at the time of 
sample collection [6]. 
Chronic and recurrent inflammation activates the immune system, elevating the demand for 
immune cells, damaging tissues and forcing cell replication. This can ultimately eventuate a state 
of replicative senescence in most cells. Replicative senescence is when cells can no longer divide 
to form new cells. These senescent cells secrete pro-inflammatory markers such as IL-6 and IL-
1a[7]. The most commonly used marker for replicative senescence is telomere length (TL). 
Telomeres function as a non-coding protective end-region of chromosomes. Due to the DNA end-
replication inefficiency of polymerases, chromosomes shorten every cell division. After a certain 
number of divisions, the threshold of attrition is reached, cell-cycle arrest occurs and eventuates 
the senescent state. Telomeres therefore are indicative of the number of divisions the cell lineage 
has undergone and are a measure of replicative senescence. 
Since recurrent and chronic inflammation leads to replicative senescence, which in turn 
contributes to a pro-inflammatory environment, measuring replicative senescence by TL has 
been a subject of scrutiny in inflammatory diseases[8]. Telomere shortening has been repeatedly 
associated with multiple inflammatory diseases. Previously, TL has been associated with lifespan, 
although this remains controversial, and with cardiovascular disease[9]. The latter association 
has been recently substantiated in a large meta-analysis including over 50.000 individuals[10] 
This study showed a significantly increased relative risk for developing cardio- and 
  
cerebrovascular disease in the tertile of the population with the shortest telomeres. Causality 
between senescence and cardiovascular diseases is supported by the presence of a high number 
of senescent cells in atherosclerotic plaques, enhancing inflammation and decreasing recovery 
potential. Endothelial cells, vascular smooth muscle cells (VSMC) and immune cells are involved. 
The reduced proliferative capacity of endothelial cells and VSMCs, together with the pro-
inflammatory environment lead to plaque instability, preluding vascular events[11–13]. 
Gout is often accompanied by cardiovascular comorbid conditions including myocardial 
infarction and cerebrovascular events, which lead to an increased morbidity and decreased life 
span[14,15]. Gout is also associated with metabolic syndrome, diabetes and renal failure, which 
in turn are predictors for cardiovascular disease. However, patients with gout remain at higher 
risk for developing cardiovascular disease after correction for these variables[16]. 
We hypothesize that chronic and recurrent acute inflammation in gout accelerates replicative 
senescence, increasing the risk of cardiovascular disease. That is, patients with gout with the 
highest burden of replicative senescence, will also have the highest burden of cardiovascular 
disease. To test our hypothesis, we investigated the most studied hallmark of replicative 
senescence, TL of PBMCs in two independent cohorts consisting of patients with gout and healthy 
individuals, both with and without cardiovascular disease. Also, we investigated telomere 
dynamics in various immune cell-subsets, scrutinized TL in a follow-up cohort and quantified 
hTERT (encoding human telomere reverse transcriptase) gene expression.  
  
Methods 
Discovery cohort and validation cohort 
In our discovery cohort, we compared TL of PBMCs in 145 patients with gout with 273 Dutch 
participants (Supplementary files, table 1). In our validation cohort, we assessed TL in PBMCs 
collected from 474 Caucasian patients with gout and 293 healthy participants participating from 
New Zealand (Supplementary files, table 1). 
This study was performed according to the guidelines of the Declaration of Helsinki and meets 
the ethical approval of the Ethical and Review committee of the University Medical Centre of 
Utrecht, Rijnstate hospital in Arnhem (both Netherlands) and the Multi-Region Ethics Committee 
in New Zealand. All the participants in this study gave their informed consent to participate. 
Isolation of mononuclear immune cell-subsets 
Mononuclear cell-subsets were sorted from total PBMCs isolated by Ficoll (Ficoll-Paque Plus, GE 
Healthcare) from peripheral blood of 10 Dutch patients with gout and 11 healthy participants 
(Supplementary files, table 3). Sorting the mononuclear cell-subsets was performed using 
fluorescence activated cell sorting (FACS) (FACSAria_III, BD Biosciences) to separate the cells 
according to the expression of cellular surface molecules; CD3+/CD56-/CD4+ for T helper 
lymphocytes, CD3+/CD56-/CD8+ for cytotoxic T lymphocytes, CD19+/CD20+ for B lymphocytes, 
CD14+ monocytes, CD3-/CD56+ NK cells and CD123 (IL3RA)+ / CD304 (BDCA4)+ pDCs. 
Telomere Length Measurements 
DNA of PBMCs was extracted using a standard salting-out protocol. Absolute TL 
quantification[17] modified with synthetic standards as described by O’Connell et al., was 
performed using the Quantitative Polymerase Chain Reaction (q-PCR) method[18]. 
Human telomerase reverse transcriptase (hTERT) gene expression 
  
Human telomerase reverse transcriptase (hTERT) gene expression level was quantified using 
synthesized cDNA (Biorad iScript kit) from RNA that was extracted from the PBMCs. Patients with 
gout (N=64) and healthy participants (N=89) from the Dutch cohort were randomly chosen. 
Quantstudio QPCR apparatus with Taqman assay (Applied Biosystems) were used to perform 
QPCR under conditions as specified by the manufacturer. To normalize the hTERT gene 
expression, the housekeeping GUSB and GAPDH genes were included. A similar method was used 
to assess hTERT gene expression in 10 patients with gout and 11 healthy participants immune 
cell subtypes separately. 
Statistical analyses 
For statistical analysis, IBM SPSS Statistics v23 (SPSS, Chicago, IL; 60606 U.S.A.) and Graphpad 
Prism v6 (GraphPad Software, San Diego, California) applications were applied. TL (in kilobase 
pairs) of patients with gout and healthy participants were log-transformed to normalize the 
distribution. A two-tailed T test was used, when appropriate with Welch’ correction for 
comparing the unequal variances between the groups. Three independent linear regression 
models were applied to separately estimate: (A) the interpolation between TL and age, gender, 
smoking, cardiovascular disease, heart failure, stroke (non-fatal), MI (non-fatal), angina pectoris, 
systolic and diastolic blood pressure, BMI (kg/m2), serum UA level (mmol/L) and creatinine level 
(µmol/L) in patients and healthy individuals, (B) the association between TL and the presence of 
cardiovascular events (heart failure, stroke (non-fatal), MI (non-fatal), angina pectoris and age 
severally in individuals with gout and (C) the relation between TL and gout hallmarks including 
attack frequency, age at the first attack, disease duration, serum UA level (mmol/L), creatinine 
level (µmol/L) severally in patients group (Table 2). 
In addition, the difference in TL between gout patients with or without cardiovascular events (A) 
and separately the association between flare frequency and cardiovascular events (angina 
pectoris, heart failure, myocardial infarction (non-fatal) and stroke (non-fatal)) (B) are 
represented in supplementary files, table 4. Univariate analysis was performed to examine the 
  
effect of variables such as gender, age, smoking, BMI and creatinine levels on TL (Supplementary 
file, table 5). Where appropriate, two-tailed Pearson or Spearman bivariate correlations were 
applied to assess the correlation between the variables (P<0.05). The Bonferroni correction was 
applied to account for multiple testing.  
  
Results 
Demographics 
Baseline characteristics of participants from the Netherlands and New Zealand are summarised 
in table 1. 
Table 1. Baseline characteristics of Dutch and New Zealand patients and healthy participants. 
 
  Gout (n=619) 
Healthy participants 
(n=566) 
P Value 
Male n (%) 489 (79.00)  398 (70.32)  0.247 
Age (mean ± SD) 62.8 ± 14.15 59.60 ± 13.67 0.0001 
Age at the first flare 
(mean ± SD) 
51.12 ± 16.75 - - 
Disease duration (year) 
(mean ± SD) 
12.90 ± 12.28 - - 
Colchicine (yes) n (%) 254 (50.50) 1 (0.17) 0.247 
NSAID (yes) n (%) 353 (75.50) 2 (0.35) 0.433 
Allopurinol (yes) n (%) 
(mean 200mg/day)  
337 (67.10)  1 (0.17)  0.0001 
Corticosteroids (yes) n 
(%) 
197 (40.20)  1 (0.17) 0.643 
CVD (yes/no) n (%) 270 (43.62) 43 (7.59)  0.0001 
Diabetes (type 2) (yes) n 
(%) 
87 (14.02)  19 (3.36)  0.0001 
Stroke (yes/no) n (%) 43 (6.95)  67 (11.83) 0.0001 
Myocardial infarction 
(non-fatal) (yes) n (%) 
70 (8.60)  66 (11.60)  0.054 
Heart failure (yes) n (%) 70 (11.31)  64 (11.31)  0.270 
Angina pectoris (yes) n 
(%) 
37 (5.98)   7 (1.24) 0.0001 
Creatinine level 
(µmol/L) (mean ± SD) 
105.73 (± 39.38) 93.44 (± 30.29) 0.0001 
Body mass index 
(kg/m2) (mean ± SD) 
29.73 (± 5.60) 28 (±6.37)  0.0001 
Smoking (yes) n (%) 51 (8.24) 5 (0.90) 0.0001 
Serum urate (mmol/L) 
(mean ± SD) 
0.43 (± 0.13) 0.35 (± 0.10) 0.0001 
Total number of flares 
per year (mean ± SD) 
8.75 ± (12.67) - - 
Presence of tophi 
(yes/no) n (%) 
116 (21.40) - - 
Systolic blood pressure 
(mm Hg) (mean ± SD)  
139.90 (± 20.55) 136 (± 17.64) 0.039 
Diastolic blood pressure 
(mm Hg) (mean ± SD) 
80.40 (± 11.83) 80.00 (± 9.62) 0.559 
Telomere length (total 
leukocytes) (mean ± SD) 
5924.90(±8617.76) 8242.70 (± 8482.00) 0.0001 
  
The data are presented as mean ± SD. The significance of the association between the 2 classified subgroups of 
gout and healthy participants was tested using Fisher's exact test (categorical values) and Mann–Whitney U test 
(non-parametrical continues values) (P<0.05). 
PBMCs from patients with gout have shorter telomeres compared to their healthy 
counterparts in two unrelated cohorts 
Within our Dutch discovery cohort, we analysed the TL of PBMCs of 273 healthy participants and 
145 patients with gout and correlated the results with their age in year. The TL in patients with 
gout was significantly shorter than healthy participants (supplementary files, table 1). In patients 
with gout, linear regression analyses demonstrated no association between age and TL (P>0.05, 
R2=0.002853) (telomere shortening=0.002082*age+4.01). This was in contrast to the significant 
inverse/negative correlation between TL and age in healthy participants (P<0.0001, R2=0.3721) 
(Telomere shortening=-0.02180*age+5.31) (Supplementary figure 1).  
Next our results in the independent cohort of NZ Caucasian, showed that TL was significantly 
shorter in patients with gout (N=474) as compared to healthy participants (N=293) 
(supplementary table 2). Moreover, we found a negative association between TL and age in gout 
patients (P=0.0014, R2=0.02276) (Telomere erosion= -0.004926*age+3.51). In healthy 
participants, we found a negative association with age (P<0.0001, R2=0.111) (Telomere erosion=-
0.01089*age+3.94) (Supplementary files, table 2) (Supplementary figure 2). 
Given the similarities in TL of PBMCs in both the discovery and replication cohort, we pooled the 
data (Figure 1). When corrected for age, patients with gout have significantly shorter telomeres 
in PBMCs as compared to healthy participants (P<0.0001). TL correlates negatively with age in 
patients with gout (P=0.0010, R2=0.01873) (TL=-0.006084*X+3.79). Similarly, PBMCs TL in 
healthy participants was inversely correlated with age (P<0.0001, R2=0.02847) (TL=-
0.006349*X+3.99). 
Finally, we had access to follow-up data on TL from 9 patients with gout involved in the Dutch 
cohort of whom 88.90% were male of 46 to 87 years old with a median age of 63 years. The time 
period between the inclusion date and the follow-up at the second time-point was from 1 to 11 
  
month with an average of 4.33 months. There was no (P=0.34) change in TL of the same patients 
with gout measured at two different time points (T1=4.20Kbp and T2=4.29Kbp). 
Gout and cardiovascular disease have an independent and cumulative effect on telomere 
attrition 
Since gout is strongly associated with cardiovascular disease, and cardiovascular disease has 
been associated with shorter telomeres, we investigated their separate effects. We included both 
patients with gout and participants with chronic heart disease (CHD), non-fatal myocardial 
infarction, non-fatal stroke and angina pectoris (Figure 2). Consistent with previous reports, 
healthy participants without cardiovascular disease had longer telomeres (P=0.04) as compared 
to healthy participants with cardiovascular disorders. The presence of cardiovascular disease in 
patients with gout resulted in significantly shorter telomeres (P=0.0001) compared to individuals 
with gout only. Moreover, TL in patients with gout without cardiovascular disease was shorter 
(P=0.0037) as compared to matched healthy individuals (Figure 2). Consequently, both gout and 
cardiovascular disease eventuated even shorter telomeres compared to healthy participants 
(P=0.005). Patients with cardiovascular disease concomitant with gout, demonstrated shorter 
telomeres (P<0.0001) as compared to healthy individuals without any comorbidities. 
In the linear regression model involving both patients with gout and healthy individuals, gout 
(P=0.008), cardiovascular disease (P=0.023) and heart failure (P=0.01) were independently 
influencing TL (Table 2A). Of note, although all the continuous variables mentioned in table 2 
were included in this model, gout, cardiovascular disease and heart failure remained in the model 
as significantly associated with TL. Moreover, in a linear regression model, cardiovascular disease 
(P=0.001) and myocardial infarction (P=0.016) influenced telomere attrition in the gout 
population (Table 2B). Additionally, in a separately performed independent linear regression 
model, the age at the first gout event (P=0.04), frequency of gouty flares (P=0.005) and the disease 
duration (P=0.035) were the most significant hallmarks of gout associating with shorter 
telomeres (Table 2C). 
  
Table 2. Multiple linear regression models for telomere length measurements in patients and 
healthy participants. 
    
Number of 
participants 
Standardized β 
Standard 
error 
P Value 
A Gout 619 -0.23  0.01 0.008 
 Cardiovascular 
disease 
313 -0.19  0.02 0.023 
  Heart failure 134 -0.22  0.01 0.010 
B 
Cardiovascular 
disease 
270 -0.55 0.02 0.001 
  
Myocardial infarction 
(non-fatal) 
70 -0.40 0.01 0.016 
  
Mean ± SD Standardized β 
Standard 
error 
P Value 
C 
Multiple number of 
flares 
8.75 ± 12.67 -0.30  2.02 0.005 
 Age at the first attack 
51.12 ± 
16.75 
-0.05  0.71 0.040 
  Disease duration 
12.90 ± 
12.28 
-0.22  0.52 0.035 
Table 2A. Demonstrates the variables significantly associated with TL involving patients with gout and healthy 
individuals assessed using multiple linear regression model. Age, gender, smoking, cardiovascular disease, heart 
failure, stroke (non-fatal), MI (non-fatal), angina pectoris, systolic and diastolic blood pressure, BMI (kg/m2), 
serum UA level (mmol/L) and creatinine level (µmol/L) were included in the model as independent variables 
(P<0.05). 
Table 2B. Includes the results of multiple linear regression analysis associating TL with cardiovascular events 
(heart failure, stroke (non-fatal), MI (non-fatal), angina pectoris and age only in individuals with gout (P<0.05). 
Table 2C. Represents multiple linear regression analysis results where the association between TL and gout 
hallmarks (attack frequency, age at the first attack, disease duration, serum UA level (mmol/L), creatinine level 
(µmol/L)) was tested (P<0.05). 
 
Furthermore, analysis revealed significantly shorter telomeres in patients with gout and 
cardiovascular events compared to gout patients without cardiovascular events (Supplementary 
files, table 4A). According to the linear regression model, however, there was no association 
between the flare frequency and cardiovascular events in patients with gout (Supplementary 
files, table 4B). 
Treatment might inhibit inflammation induced telomere erosion in immune-cells of gout 
patients 
Since the majority of gout patients were receiving anti-inflammatory and/or urate-lowering 
treatment, we tested if any treatment had any effect on the extend of telomeres. The treatment 
included allopurinol (mean 200mg/day), colchicine, corticosteroids, NSAIDs or a combination of 
these drugs. There was no significant difference between TL of treated (TL(±SD) = 2301 ± 
  
2333.79) and untreated patients (TL(±SD) = 2998 ± 5166.92) (N=23) (P=0.584). The insignificant 
difference in TL might be due to low number of untreated patients. Since the patients were treated 
with more than one drug, any drug specific effect on the extend of TL was intractable. 
Telomere shortening is not specific for certain immune cell-subsets 
To identify immune cells with a dominant effect on the complications associated with senescence, 
we investigated the percentage and TL of mononuclear cell-subsets of 10 healthy participants and 
10 patients with gout (Supplementary files, table 3). 
In patients with gout, there were no significant difference in CD4+ T lymphocytes (24.42%), CD8+ 
Cytotoxic T lymphocytes (6.74%), CD19+ B lymphocytes (7.02%), CD14+ monocytes (7.75%), NK 
cells (7.92%) and CD123+/CD304+ pDCs (0.02%) of patients with gout as compared to healthy 
participants’ cell-subsets that were 33.19% (P=0.11), 8.98% (P=0.061), 10.07% (P=0.157), 6.28% 
(P=0.90), 7.38% (P=0.52) and 0.11% (P=0.8) respectively (Mann-Whitney U-test, P<0.05). 
Moreover, CD19+ B lymphocytes of patients with gout had the longest telomeres and 
CD123+/CD304+ pDCs the shortest. The longest and shortest telomeres in healthy participants 
were also respectively in CD19+ B lymphocytes and CD123+/CD304+ pDCs. In direct comparison 
between cell-subsets from patients with gout and healthy individuals we did not observe a 
significant difference in TL. 
Telomerase activity is similar in patients with gout and healthy participants 
There was no correlation between hTERT gene expression level and TL in total PBMCs. There was 
no significant difference in the mean fold change of hTERT expression level of patients with gout 
(P=0.921, R2=0.013) and healthy participants (P=0.087, R2=-0.264) (Figure 3). Similarly, there 
was no correlation between hTERT gene expression level and TL of the immune cell-subset 
(Supplementary file, table 3).  
  
Discussion 
In this study, we show that patients with gout have shorter telomeres than healthy participants, 
reflecting increased cellular senescence. Telomere shortening was strongly associated with the 
number of gouty flares. Both gout and cardiovascular disease were independently associated with 
shorter telomeres. This is to our knowledge the first study to show telomere erosion in patients 
with gout, compared to healthy participants. 
There are several strengths of this study that minimise the risk of chance observation or 
population bias. We exploited an independent replication cohort where DNA material was 
isolated and measured using a similar protocol. We observed intriguing TL differences in 
participants of both Dutch and New Zealand cohorts. It has been described previously that there 
are large differences in telomere length between Caucasians from different European descent. 
For instance, telomeres of inhabitants from Belgium have been shown to be six-fold longer as 
compared to inhabitants from Italy and are approximately twice as long as inhabitants from the 
United Kingdom, Ireland and Scotland[19,20]. Since the Caucasians from New Zealand have 
ancestors primarily from Britain and the Dutch are more closely related to the Belgians, our 
findings are most likely caused by an ancestral difference[20–22]. 
To rule out an effect of differences in telomere maintenance between patients with gout and 
healthy participants, we tested hTERT gene expression which has been shown to be a reliant 
proxy marker to measure telomerase activity[22]. We assessed hTERT gene expression in PBMCs 
and cell-subsets of patients with gout and healthy individuals. We did not observe any difference 
in hTERT gene expression level which underscores any bias due to telomerase activity as very 
unlikely. To minimize technical issues, we used the same protocols and same machines to 
measure telomere length. 
To elucidate more details on underlying facets contributing to telomere attrition in gout, we 
quantified absolute TL in CD4+ and CD8+ T cells, CD19+ B cells, CD14+ monocytes, NK cells and 
pDCs in patients with gout and matched healthy participants. TL of CD4+ and CD8+ T cells, CD19+ 
  
B cells, CD14+ monocytes, NK cells and pDCs showed no significant difference. In immune cell-
subtypes of patients with gout, telomere shortening showed a slightly declining trend as 
compared to healthy participants. However, the number of included participants is insufficient to 
empower us to draw definite conclusions from these results. Multiple research groups have 
corroborated a strong link between chronic inflammation and decrease of TL in cell-subsets. For 
instance, studies on human immunodeficiency virus (HIV), elucidated the link between chronic 
infection and telomere attrition in CD4+  and CD8+ T cells[23,24]. The replicative senescence of T 
lymphocytes is not limited to HIV, since it is broadly investigated in association with 
malignancies[25], autoimmune disorders[26] and environmental mediators[27,28]. In 
autoimmune diseases, telomere erosion in lymphocytes has been less well delineated. Telomere 
erosion in CD14+ monocytes, however, was shown to be significantly associated with pro-
inflammatory behaviour and, of high relevance for our findings, thereby accelerated 
atherosclerotic plaque formation[29]. In the elderly, diminished NK cell function was significantly 
associated with the extent of telomere erosion[30,31]. The literature describing telomere 
attrition in pDCs is rather poor and requires additional investigations. Taken together, it is known 
from the literature that TL of various immune cell-subsets can be impacted when chronic or 
recurrent inflammation is present. In our study, we could not pinpoint a single cell-subset 
responsible for the shortening of telomeres as observed in the PBMCs from the gout population. 
Since the effects on TL difference in PBMCs only came apparent in a large cohort with hundreds 
of patients, we believe that our lack of findings is most likely caused by a lack of power in the 
subset analyses. On the other hand, since we observe such similar findings between subsets, it 
seems to indicate that there is not one single cell-subset responsible for a large effect on TL in the 
whole PBMC population. The latter might point to a more generalizable effect in the cell-subset 
populations. Additionally, the shifting of naïve T lymphocytes towards a memory-like subset 
remains to be delineated. whereby the CD28 marker repertoire might be indicative of chronic 
inflammation-induced activation in T lymphocytes[32]. 
  
We conclude that the shorter telomeres observed in the gout population are most likely caused 
by increased PBMCs turnover due to on-going or frequent inflammatory episodes. This is 
consistent with association of reduced TL with increased flare frequency. In various tissues and 
cell-subtypes, accelerated cell-turnover is inversely associated with replicative senescence. In 
disorders involving accelerated oxidative injury and chronic immune system activation as the 
main manifestation, such as systemic lupus erythematosus [33], rheumatoid arthritis[32] and 
systemic sclerosis[34], enhanced cell-turnover and telomere erosion has been extensively 
described. Furthermore, we observed no significant TL difference in treated patients with gout as 
compared to patients without treatment. In addition, patients with the most frequent flares had 
the shortest telomeres. This might indirectly imply a modulating effect of inflammation on 
telomere length and thereby replicative senescence. 
The results of our study underline the strong association between inflammation, senescence and 
cardiovascular disease, as suggested previously[35]. Recently, it has become apparent that 
rheumatic diseases confer risk of cardiovascular disease development. In rheumatoid arthritis, 
this risk approaches the risk of patients with diabetes[36]. The pathogenesis of this increased risk 
is largely enigmatic, but is proposed to arise from a chronic inflammatory environment, causing 
vascular damage and plaque formation[37,38]. The occurrence of atherosclerotic plaques has 
been related to an increasing chronological age[11]. On the other hand, there is a large role for 
biological ageing as well which has been demonstrated by the influx of pro-inflammatory 
senescent immune cells in the plaque contributing to plaque instability and rupture and 
eventually cardiovascular and cerebrovascular events[39]. The connection between replicative 
senescence and the presence of cardiovascular disease has been described before in the 
literature[40]. Likewise, the prevalence of myocardial infarction in the elderly with shorter 
leukocytes’ TL is about 3 times higher[41,42,40]. A recent systemic review confirmed this 
association by combining the telomere data and vascular morbidity of over 50.000 
individuals[10]. 
  
In summary, we present decreased TL as a feature of gout and confirm TL as an independent 
factor associated with flare frequency and cardiovascular disease. These data suggest that 
intensive treatment of gout may prevent replicative senescence and subsequently reduce the 
associated cardiovascular risk. However large prospective studies are needed to test this 
possibility.  
  
ACKNOWLEDGEMENTS AND FUNDING INFORMATION 
This study was partly funded by the NWO VIDI grant of T.R.D.J. Radstake. J.C.B. is supported by a 
VENI Award from the Netherlands Organization for Scientific Research (N.W.O. project number 
91614041). The New Zealand portion of the study was funded by the Health Research Council of 
New Zealand, New Zealand Lottery Health, Arthritis New Zealand and the University of Otago, 
New Zealand.  
  
ETHICAL APPROVAL INFORMATION 
This study was performed according to the guidelines of the Declaration of Helsinki and meets 
the ethical approval of the Ethical and Review committee of the University Medical Centre of 
Utrecht, Rijnstate hospital in Arnhem (both Netherlands) and the Multi-Region Ethics Committee 
in New Zealand. All the participants in this study gave their informed consent to participate.  
  
COMPETING INTERESTS 
Non declared.  
  
AUTHORSHIP 
N.V. contributed to research design, performed experiments, analyzed data and contributed to 
writing the paper; L.B.E.K., E.V.L., N.D., L.K.S., T.R.M., M.J., contributed to patients’ recruitment, 
interpreted data, and contributed to writing the manuscript; C.W. performed experiments and 
contributed to data analysis; M.R., P.G.S., interpreted data, and contributed to writing the 
manuscript; J.C.A.B. and T.R.D.J.R designed research, interpreted data and contributed to writing 
the manuscript. 
 
AUTHOR CONTRIBUTION 
All authors approved the final version after being involved in drafting and revising the article for 
important intellectual content. As the corresponding author, Dr. Broen had full access to the data 
and takes responsibility for the accuracy of the performed analysis and the integrity of the data.  
  
LICENCE FOR PUBLICATION 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf 
of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide 
basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be 
published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all 
subsidiary rights, as set out in our licence (http://journals.bmj.com/site/authors/editorial-
policies.xhtml#copyright) and the Corresponding Author accepts and understands that any 
supply made under these terms is made by BMJPGL to the Corresponding Author. 
 
DATA SHARING STATEMENT 
Other than the included data, there is no additional data available regarding this manuscript.  
  
Reference 
1  Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;6736:1–14. 
doi:10.1016/S0140-6736(16)00346-9 
2  Richette P, Bardin T. Gout. Lancet 2010;375:318–28. doi:10.1016/S0140-
6736(09)60883-7 
3  Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial 
infarction. Arthritis Rheum 2006;54:2688–96. doi:10.1002/art.22014 
4  Choi HK. A prescription for lifestyle change in patients with hyperuricemia and 
gout. Curr Opin Rheumatol 2010;22:165–72. 
doi:10.1097/BOR.0b013e328335ef38 
5  VanItallie TB. Gout: epitome of painful arthritis. Metabolism 2010;59 Suppl 1:S32-
6. doi:10.1016/j.metabol.2010.07.009 
6  Kienhorst LBE, Van Lochem E, Kievit W, et al. Gout is a chronic inflammatory 
disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 
8/myeloid-related protein 14 complex, and an altered proteome are associated 
with diabetes mellitus and cardiovascular disease. Arthritis Rheumatol 
2015;67:3303–13. doi:10.1002/art.39318 
7  Dmitrieva OS, Shilovskiy IP, Khaitov MR, et al. Interleukins 1 and 6 as Main 
Mediators of Inflammation and Cancer. Biochem 2016;81:80–90. 
doi:10.1134/S0006297916020024 
8  Zhang J, Rane G, Dai X, et al. Ageing and the telomere connection: An intimate 
relationship with inflammation. Ageing Res Rev 2016;25:55–69. 
doi:10.1016/j.arr.2015.11.006 
9  López-Otín C, Blasco M a, Partridge L, et al. The hallmarks of aging. Cell 
2013;153:1194–217. doi:10.1016/j.cell.2013.05.039 
10  Haycock PC, Heydon EE, Kaptoge S, et al. Leucocyte telomere length and risk of 
cardiovascular disease: systematic review and meta-analysis. BMJ 
2014;349:g4227. doi:10.1136/bmj.g4227 
11  Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human 
atherosclerosis: Role of telomere in endothelial dysfunction. Circulation 
2002;105:1541–4. doi:10.1161/01.CIR.0000013836.85741.17 
12  Gorenne I, Kavurma M, Scott S, et al. Vascular smooth muscle cell senescence in 
atherosclerosis. Cardiovasc Res 2006;72:9–17. 
doi:10.1016/j.cardiores.2006.06.004 
13  Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo 
telomere-based senescence in human atherosclerosis: Effects of telomerase and 
oxidative stress. Circ Res 2006;99:156–64. 
doi:10.1161/01.RES.0000233315.38086.bc 
14  McAdams-DeMarco M a, Maynard JW, Baer AN, et al. Hypertension and the risk of 
incident gout in a population-based study: the atherosclerosis risk in communities 
  
cohort. J Clin Hypertens (Greenwich) 2012;14:675–9. doi:10.1111/j.1751-
7176.2012.00674.x 
15  Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: 
cause and effect? Curr Rheumatol Rep 2010;12:118–24. doi:10.1007/s11926-010-
0084-3 
16  Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care 
2005;11:435–42. doi:3040 [pii] 
17  Cawthon RM, Weiss R, Xu G, et al. A major segment of the neurofibromatosis type 
1 gene: cDNA sequence, genomic structure, and point mutations. Cell 
1990;62:609.http://www.ncbi.nlm.nih.gov/pubmed/2116238 
18  O’Connell P, Viskochil D, Buchberg  a M, et al. The human homolog of murine Evi-2 
lies between two von Recklinghausen neurofibromatosis translocations. Genomics 
1990;7:547–54.http://www.ncbi.nlm.nih.gov/pubmed/2117565 
19  Salpea KD, Nicaud V, Tiret L, et al. The association of telomere length with paternal 
history of premature myocardial infarction in the European Atherosclerosis 
Research Study II. J Mol Med 2008;86:815–24. doi:10.1007/s00109-008-0347-x 
20  Eisenberg DTA, Salpea KD, Kuzawa CW, et al. Substantial variation in qPCR 
measured mean blood telomere lengths in young men from eleven European 
countries. Am J Hum Biol 2011;23:228–31. doi:10.1002/ajhb.21126 
21  Chiang YJ, Calado RT, Hathcock KS, et al. Telomere length is inherited with resetting 
of the telomere set-point. Proc Natl Acad Sci U S A 2010;107:10148–53. 
doi:10.1073/pnas.0913125107 
22  Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells 
leads to elongation of telomeres and extended replicative life span. Curr Biol 
1998;8:279–82. doi:10.1016/S0960-9822(98)70109-5 
23  Jiménez VC, Wit FWNM, Joerink M, et al. T-Cell Activation Independently Associates 
With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral 
Treatment. J Infect Dis 2016;:jiw146. doi:10.1093/infdis/jiw146 
24  Gianesin K, Noguera-Julian A, Zanchetta M, et al. Premature aging and immune 
senescence in HIV-infected children. Aids 2016;:1. 
doi:10.1097/QAD.0000000000001093 
25  Press D. Shorter telomere length of T-cells in peripheral blood of patients with lung 
cancer. 2016;:2675–82. 
26  Fessler J, Raicht A, Husic R, et al. Premature senescence of T-cell subsets in axial 
spondyloarthritis. Ann Rheum Dis 2015;:1–7. doi:10.1136/annrheumdis-2014-
206119 
27  Lin J, Cheon J, Brown R, et al. Systematic and Cell Type-Specific Telomere Length 
Changes in Subsets of Lymphocytes. J Immunol Res 2015;2016:9. 
doi:10.1155/2016/5371050 
28  Silva LCR, de Araújo AL, Fernandes JR, et al. Moderate and intense exercise 
lifestyles attenuate the effects of aging on telomere length and the survival and 
  
composition of T cell subpopulations. Age (Omaha) 2016;38:1–16. 
doi:10.1007/s11357-016-9879-0 
29  Merino A, Buendia P, Martin-Malo A, et al. Senescent CD14+CD16+ monocytes 
exhibit proinflammatory and proatherosclerotic activity. J Immunol 
2011;186:1809–15. doi:10.4049/jimmunol.1001866 
30  Access O, Ai J, Smith B, et al. Original Article. 2012;:187–99. 
doi:10.1038/ijos.2012.26 
31  Ouyang Q, Baerlocher G, Vulto I, et al. Telomere length in human natural killer cell 
subsets. Ann N Y Acad Sci 2007;1106:240–52. doi:10.1196/annals.1392.001 
32  Steer SE, Williams FMK, Kato B, et al. Reduced telomere length in rheumatoid 
arthritis is independent of disease activity and duration. Ann Rheum Dis 
2007;66:476–80. doi:10.1136/ard.2006.059188 
33  Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with 
systemic lupus erythematosus. Arthritis Rheum 2013;65:1319–23. 
doi:10.1002/art.37895 
34  MacIntyre  a, Brouilette SW, Lamb K, et al. Association of increased telomere 
lengths in limited scleroderma, with a lack of age-related telomere erosion. Ann 
Rheum Dis 2008;67:1780–2. doi:10.1136/ard.2007.086652 
35  Aulinas A, Ram??rez MJ, Barahona MJ, et al. Dyslipidemia and chronic inflammation 
markers are correlated with Telomere Length shortening in Cushing’s syndrome. 
PLoS One 2015;10:1–15. doi:10.1371/journal.pone.0120185 
36  van Halm VP, Peters MJL, Voskuyl  a E, et al. Rheumatoid arthritis versus diabetes 
as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE 
Investigation. Ann Rheum Dis 2009;68:1395–400. doi:10.1136/ard.2008.094151 
37  Sattar N, McCarey DW, Capell H, et al. Explaining How ‘High-Grade’ Systemic 
Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation 
2003;108:2957–63. doi:10.1161/01.CIR.0000099844.31524.05 
38  van Zonneveld  a J, de Boer HC, van der Veer EP, et al. Inflammation, vascular injury 
and repair in rheumatoid arthritis. Ann Rheum Dis 2010;69 Suppl 1:i57-60. 
doi:10.1136/ard.2009.119495 
39  van Oostrom O, Velema E, Schoneveld AH, et al. Age-related changes in plaque 
composition: a study in patients suffering from carotid artery stenosis. Cardiovasc 
Pathol 2005;14:126–34. doi:10.1016/j.carpath.2005.03.002 
40  Epel ES, Merkin SS, Cawthon R, et al. The rate of leukocyte telomere shortening 
predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY) 
2009;1:81–8. 
41  Brouilette S, Singh RK, Thompson JR, et al. White cell telomere length and risk of 
premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003;23:842–6. 
doi:10.1161/01.ATV.0000067426.96344.32 
42  Ogami M, Ikura Y, Ohsawa M, et al. Telomere Shortening in Human Coronary Artery 
Diseases. Arterioscler Thromb Vasc Biol 2004;24:546–50. 
  
doi:10.1161/01.ATV.0000117200.46938.e7  
  
 
  
  
 
